142 related articles for article (PubMed ID: 11943931)
1. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Zangari M; Saghafifar F; Anaissie E; Badros A; Desikan R; Fassas A; Mehta P; Morris C; Toor A; Whitfield D; Siegel E; Barlogie B; Fink L; Tricot G
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):187-92. PubMed ID: 11943931
[TBL] [Abstract][Full Text] [Related]
2. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G
Blood; 2001 Sep; 98(5):1614-5. PubMed ID: 11520815
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G
Clin Lymphoma; 2003 Jun; 4(1):32-5. PubMed ID: 12837152
[TBL] [Abstract][Full Text] [Related]
5. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Bradbury CA; Craig Z; Cook G; Pawlyn C; Cairns DA; Hockaday A; Paterson A; Jenner MW; Jones JR; Drayson MT; Owen RG; Kaiser MF; Gregory WM; Davies FE; Child JA; Morgan GJ; Jackson GH
Blood; 2020 Aug; 136(9):1091-1104. PubMed ID: 32438407
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
Morgan GJ; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Cook G; Feyler S; Johnson PR; Rudin C; Drayson MT; Owen RG; Ross FM; Russell NH; Jackson GH; Child JA;
Haematologica; 2012 Mar; 97(3):442-50. PubMed ID: 22058209
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Badros A; Morris C; Zangari M; Barlogie B; Tricot G
Leuk Lymphoma; 2002 Jun; 43(6):1267-71. PubMed ID: 12152995
[TBL] [Abstract][Full Text] [Related]
8. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G
Blood; 2002 Aug; 100(4):1168-71. PubMed ID: 12149193
[TBL] [Abstract][Full Text] [Related]
9. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic events during treatment with thalidomide.
Urbauer E; Kaufmann H; Nösslinger T; Raderer M; Drach J
Blood; 2002 Jun; 99(11):4247-8. PubMed ID: 12043695
[No Abstract] [Full Text] [Related]
13. Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
Kovacs MJ; Davies GA; Chapman JA; Bahlis N; Voralia M; Roy J; Kouroukis CT; Chen C; Belch A; Reece D; Zhu L; Meyer RM; Shepherd L; Stewart KA
Br J Haematol; 2015 Feb; 168(4):511-7. PubMed ID: 25302852
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.
Martinelli I; Battaglioli T; Bucciarelli P; Passamonti SM; Mannucci PM
Circulation; 2004 Aug; 110(5):566-70. PubMed ID: 15262837
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
[TBL] [Abstract][Full Text] [Related]
16. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G
J Clin Oncol; 2003 Jul; 21(14):2732-9. PubMed ID: 12860952
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
18. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
Minnema MC; Breitkreutz I; Auwerda JJ; van der Holt B; Cremer FW; van Marion AM; Westveer PH; Sonneveld P; Goldschmidt H; Lokhorst HM
Leukemia; 2004 Dec; 18(12):2044-6. PubMed ID: 15470485
[No Abstract] [Full Text] [Related]
19. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
